BioSpace News Archive

Adulhelm’s proposed price tag of $56,000 per patient per year is hardly the most expensive drug on the market, but controversy regarding packaging and pricing continues.

The first nonsteroidal mineralocorticoid receptor antagonist (MRA) is approved for adults with chronic kidney disease associated with type 2 diabetes.

Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.

The hospital mobile X-Ray market was valued at US$ 1,604.92 million in 2019 and it is projected to reach US$ 3,479.79 million by 2027; it is expected to grow at a CAGR of 10.2% during 2020–2027.

It was based on data from the APOLLO trial showing the drug significantly decreased the risk of progression or death by 37% compared to dexamethasone alone.

The Viral Antigens market was valued at US$101.41 million in 2019 and is projected to reach US$ 236.80 million by 2027; it is expected to grow at a CAGR of 11.0% during 2020–2027.

The addictions therapeutics market was valued at US$ 6,691.01 million in 2019 and is projected to reach US$ 10,735.94 million by 2027; it is expected to grow at a CAGR of 6.2% from 2020 to 2027.

Menagen Pharmaceutical Industries and Chong Kun Dang Pharmaceutical Corp Korea announced that they have entered into a strategic partnership in the GCC market for the technology transfer and commercialization for the first biosimilar Darbepoetin alpha, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, announced that it has commenced an underwritten initial public offering of up to 7,000,000 shares of its common stock.

Lannett Company, Inc. announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product.